BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17239302)

  • 21. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.
    Stojanovic N; Lewandowski K; Salata I; Bienkiewicz M; Tuck S; Prelevic G; Press M
    Gynecol Endocrinol; 2010 Mar; 26(3):201-7. PubMed ID: 19526397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
    Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma matrix metalloproteinase-9 levels and blood pressure in short children born small for gestational age and effects of growth hormone treatment.
    Willemsen RH; van Dijk M; de Kort SW; van Toorenenbergen AW; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):264-8. PubMed ID: 18284641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K; Turpeenniemi-Hujanen T
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
    Mwaura B; Mahendran B; Hynes N; Defreitas D; Avalos G; Adegbola T; Adham M; Connolly CE; Sultan S
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):306-10. PubMed ID: 16169261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different circulating metalloproteinases profiles in women with migraine with and without aura.
    Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
    Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
    Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
    Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
    Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinases and their tissue inhibitors in children with chronic hepatitis B treated with lamivudine.
    Lebensztejn DM; Skiba E; Sobaniec-Łotowska ME; Kaczmarski M
    Adv Med Sci; 2007; 52():114-9. PubMed ID: 18217401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes.
    Kadoglou NP; Vrabas IS; Sailer N; Kapelouzou A; Fotiadis G; Noussios G; Karayannacos PE; Angelopoulou N
    Diabetes Metab; 2010 Apr; 36(2):144-51. PubMed ID: 20149706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
    Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced levels of MMP-2 and TIMP-1 in dyssegmental dysplasia.
    Uchide K; Ueno H; Takizawa N; Okada Y
    J Bone Miner Res; 2003 Feb; 18(2):381-2. PubMed ID: 12568417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
    Chen R; Zhang AR; Zhao XX; Li ZH
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
    Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
    J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus.
    Derosa G; Avanzini MA; Geroldi D; Fogari R; Lorini R; De Silvestri A; Tinelli C; Rondini G; d'Annunzio G
    Diabetes Res Clin Pract; 2005 Nov; 70(2):119-25. PubMed ID: 16188574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.